We conducted a retrospective study of PD-1 blocking antibodies (pembrolizumab or nivolumab) plus autologous CIK cells to assess the safety, effectiveness, and influence on immune function of this treatment in a total of 18 patients with advanced NSCLC. We found that disease control rate (DCR) was significantly higher in patients who received a combination of PD-1 blockade + CIK cell infusions than in those who received a PD-1 blocking antibody alone. This clinical study provides data support for further clinical trials in the future.

Pre-existing IIPs were a risk factor for ICI pneumonitis. Objective response rate and prognosis of patients with IIPs were similar to those of other patients.

We attempted to identify sentinel lymph nodes by indocyanine green in lung cancer surgery. The identification rate was 72.7%, and the accuracy rate was 100% immediately after surgery. In addition, we followed-up the cases for a long time to check for lymph node metastasis and verify whether the results of intraoperative sentinel biopsy were correct. After follow-up had been completed, the false-negative rate was 7.7% (1/13) and the accuracy rate was 93.8% (15/16) in this study.

we evaluated the first phase II prospective clinical trial to assess the efficacy and safety of osimertinib combined with bevacizumab for LM from EGFRm NSCLC. Osimertinib combined with bevacizumab is an appropriate treatment option for patients with LM from EGFRm NSCLC.

We found a novel RNF213 gene with high specificity in peripheral blood ctDNA in assisted diagnosis of lung cancer. It may be helpful about assisted diagnosis and treatment of lung cancer.

This study demonstrates that a tissue surface area >1.04 mm² and tumor cell count >375 cells had a positive effect on the analysis success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples. The criteria mentioned above will help to determine which tests should be performed; next-generation sequencing-based companion diagnostics or multiple single-gene testing.

We demonstrated that tumor growth rate (GR) predicts treatment outcome in early-stage lung cancer patients treated with SBRT. We used specific growth rate (SGR) as a metric for pretreatment GR and its median (0.43 × 10^-2) to group patients into high and low SGR cohorts. In this study, the same median SGR was validated in an independent dataset at a different cancer institution. Patients with high SGR tumors consistently had significantly lower survival and higher regional failure.

Downregulation of CADM1 could antagonize the functions of miR-423-5p inhibitor on cell proliferation and metastasis. miR-423-5p aggravated lung adenocarcinoma via downregulation of CADM1 expression.

NSCLC patients with EGFR/HER2 Ex20ins had similar genomic characteristics and distinct immune features when compared to common EGFR mutations. Patients with EGFR Ex20ins had significantly higher PD-L1 expression than those with HER2 mutations, which may be the potential reason for the different responses to PD-1/PD-L1 blockage.

Postoperative radiotherapy (PORT) has been recommended to treat patients with positive surgical margins. However, the existing evidence is controversial and high-level evidence is lacking. In our study, the PORT group had markedly, but not statistically significant, longer median OS compared with the non-PORT group in R1 resection patients. OS was significantly longer in the R1 resection patients receiving adjuvant CRT than the surgery alone group.

We demonstrated that only minimal presence of solid or micropapillary component was profoundly associated with aggressive clinicopathological features and poor prognosis after complete resection even in stage IA lung adenocarcinoma.

Our results suggest that minimal presence of these subtypes is a strong prognostic factor which should be taken into account in the risk assessment for adjuvant chemotherapy in lung adenocarcinoma.

The one-year local control rate was 83% in the durvalumab cohort and 62% in the CCRT alone cohort, which was significantly different.

The adequacy for next generation sequencing (NGS) in transbronchial lung cryobiopsy (TBLC) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) samples remains unclear. We found the mean number of genes which could not be assessed via NGS was significantly lower in TBLC samples than EBUS-TBNA samples. TBLC could obtain adequate samples with a high concentration of uncrushed tumor cells for NGS.

Here, we present a case of an elderly patient who had a complete response of non–small cell lung cancer (NSCLC) following treatment with pembrolizumab. The complete response was maintained for one and a half years after discontinuation of two years of treatment. In elderly patients with NSCLC with PD-L1 expression of more than 50%, pembrolizumab should be considered as first-line treatment with the treatment period, and mechanism suggested in this report.

The prognosis of the small cell esophageal cancer (SCEC) patient in our study was poor due to lack of treatment options. Immunotherapy plus chemotherapy might therefore be a reasonable option for selected SCEC patients.

Lung cancer that develops in lung tissue highly compressed by a giant emphysematous bulla is rare, and is difficult to diagnose. After performing intracavity drainage of a giant emphysematous bulla, the remaining lung re-expands and the bronchial shift improves; subsequently, bronchoscopy makes it possible to diagnose lung cancer in the remaining lung.

An 86-year-old male patient, who had been diagnosed with lung adenocarcinoma with BRAF V600E mutation, received dabrafenib and trametinib combination chemotherapy. The tumor shrunk rapidly; however, therapy was discontinued after 40 days because adverse events (hypoalbuminemia, peripheral edema, and pneumonia) developed. Although this targeted combination therapy seemed to cause relatively severe adverse events compared with single-agent targeted therapy in this “oldest old” elderly patient, the marked tumor shrinkage prolonged the patient's life and helped him to maintain a good general condition.